Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity lowers target price on B&M following CEO's exit

(Sharecast News) - Analysts at Canaccord Genuity lowered their target price on discount retailer B&M from 545.0p to 495.0p on Tuesday following the surprise announcement of chief executive Alex Russo's departure and a further moderation to FY25 guidance. Canaccord Genuity pointed out that Russo's departure follows the news announced in November that B&M's trading director was also set to depart in March, highlighting "significant changes" to the group's senior leadership team.

"The appointment of a new CEO will be an important catalyst and driver of sentiment in the shares," said the Canadian bank, which stood by its 'buy' rating on the stock. "Whilst further guidance reductions are disappointing, and the leadership changes unsettling, we continue to believe that the group's long-term growth opportunity remains intact.

On Canaccord's revised forecasts, B&M trades on an FY25E price-to-earnings ratio of 8.6x, something it continues to believe offers "good value", both in the context of the long-term average FY1 PER multiple of roughly 15x, but also given the "significant long-term expansion potential" both in the UK and Europe,

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.